These findings provide support for clinical trials involving PI3K pathway inhibitors, tyrosine kinase inhibitors (TKIs) and MAPK pathway inhibitors in patients with cervical cancer detected by targeted molecular screening. Here, PIK3CA is linked to cervical cancer.